Sunday 8 February 2026

The Pharmaletter

Prothena

Prothena is an Irish clinical-stage biotechnology company that develops novel monoclonal antibodies directed towards misfolded proteins or improper cell adhesion.

Company Overview

Want to Update your Company's Profile?


Latest Prothena News

Prothena provides mixed update on PRX012
29 August 2025
Roche to advance PD candidate prasinezumab into Phase III
16 June 2025
Prothena slumps on Phase III birtamimab miss
26 May 2025
Bristol Myers takes up option on Prothena’s PRX019
29 May 2024
More Prothena news >


Today's issue

The week in pharma: action, reaction and insight – week to February 6, 2026
Pharmaceutical
The week in pharma: action, reaction and insight – week to February 6, 2026
8 February 2026
Pharmaceutical
Health Canada approves Livmarli for PFIC and ALGS
7 February 2026
Biotechnology
Novartis breaks ground on San Diego biomedical research center
7 February 2026
article
Eikon’s IPO splash fades as shares tumble on debut
6 February 2026
Biotechnology
Kelun-Biotech expands label in China breast cancer market
6 February 2026
Biotechnology
FDA grants priority review for Hympavzi sBLA
6 February 2026
Biotechnology
Biogen 4th-quarter 2025 results beat forecasts
6 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze